Genmab — August 2017
-
Nu har vi vist harpet rundt i ofa og dara længe nok - rent debatmæssigt kan Jan godt gøre os den tjeneste at bringe nogle programmer frem i fase 2/3 stykker.
-
Det er jo frygteligt at se Bava løbe med al den opmærksomhed...
-
ja, det virker noget uklart, hvad den opt-in præcist går ud på. Det vil være dejligt med noget klarhed
-
Sgen skal vel til at beslutte noget. Genmab er jo gået videre i fase 2, og det hedder, at 'Seattle Genetics has the right to exercise a co-development option for any resulting ADC products at the end of Phase I clinical development', hvilket jo nok er lidt gråzoneagtigt, men alligevel..Som bekendt: https://clinicaltrials.gov/ct2/show/NCT03245736?term=tisotumab&rank=1
. -
https://clinicaltrials.gov/ct2/show/NCT02001623?term=Tisotumab&rank=3 Dette er estimeret til at slutte februar 18. Så det er vel det.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind